| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 41,570 | 41,680 | 19:30 | |
| 41,570 | 41,685 | 19:30 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 135,00 | 57 | |||
| 60,00 | 15 | |||
| 55,00 | 44 | |||
| 52,20 | 500 | |||
| 51,76 | 50 | |||
| 42,220 | 30 | |||
| 42,210 | 30 | |||
| 42,200 | 50 | |||
| 42,005 | 180 | |||
| 41,980 | 1.792 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/0qf.htm [/URL] | ||||
| 1.972 | 41,865 | |||
| 50 | 41,645 | |||
| 30 | 41,635 | |||
| 30 | 41,625 | |||
| 37 | 36,000 | |||
| 120 | 20,800 | |||
| 300 | 20,000 | |||
| 1.052 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 3.591 | 0,765 | 2.748 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 17:35:35 | 42,795 | 9 |
| 17:24:14 | 42,545 | 125 |
| 17:12:21 | 42,640 | 78 |
| 17:12:21 | 42,635 | 47 |
| 17:04:33 | 42,510 | 197 |
| 17:02:06 | 42,560 | 2 |
| 16:45:05 | 42,085 | 159 |
| 16:40:17 | 42,430 | 4 |
| 16:35:49 | 42,460 | 206 |
| 16:32:25 | 42,425 | 81 |
| 16:30:44 | 42,755 | 125 |
| 16:20:23 | 42,250 | 90 |
| 16:17:58 | 42,445 | 197 |
| 16:16:46 | 42,460 | 76 |
| 16:11:38 | 42,735 | 96 |
| 16:10:21 | 42,815 | 80 |
| 16:08:55 | 42,700 | 134 |
| 16:08:55 | 42,700 | 3 |
| 16:08:09 | 42,770 | 68 |
| 16:05:50 | 42,850 | 110 |
| Tagesumsatz Xetra | -3,365 -7,29 % | 5.996 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:18 | Moderna vor entscheidender Bewährungsprobe | 399 | LYNX Broker | Moderna steht derzeit wieder stärker im Fokus technischer Beobachter. Im Chartbild zeigen sich Hinweise auf eine Stabilisierung Den vollständigen Artikel lesen ... ► Artikel lesen | |
| MODERNA Aktie jetzt für 0€ handeln | |||||
| Fr | MODERNA INC: Stabilität als strategisches Signal | 22 | Maximilian Berger | ||
| Fr | ImmunityBio vs. Moderna: Which Biotech Has More Upside Potential? | 38 | Zacks | ||
| Mi | Moderna Stock is Soaring. Is It Too Late to Buy? | 22 | The Motley Fool | ||
| Di | Moderna stands as the best performing large-cap healthcare stock YTD | 18 | Seeking Alpha |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 18:06 | Aelis Farma Reports Its 2025 Annual Financial Results and Confirms Its 2026 Outlook | Business Wire | 2025 has been marked by several significant events: The achievement of key milestones for the Company's two drug candidates:
AEF0117: announcement of the final results of the Phase... ► Artikel lesen | |
| 16:06 | Viva Biotech Announces 2025 Annual Results: AI-Driven Drug Discovery Reinforces Industry Leadership, CDMO Commercial Products Enter Rapid Scale-Up | PR Newswire | CRO Business Sustained Recovery in Growth, AI-Enabled Drug Discovery Technology Maintained Industry-Leading AdvantagesThroughout 2025, revenue from the Company's CRO business rose from RMB810.9 million... ► Artikel lesen | |
| 14:48 | Immix Biopharma, Inc.: Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones | GlobeNewswire (Europe) | - Full enrollment of BLA-enabling trial complete, per prior guidance -- Topline NEXICART-2 Results Expected Q3 2026, followed by BLA submission and planned commercial launch -- Onboarded Chief Medical... ► Artikel lesen | |
| 18:30 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen erteilt Taisho Pharmaceutical eine Lizenz für seine RenNano-Plattform zur Entwicklung von vollständig humanen, ausschließlich aus schweren Ketten bestehenden Antikörpern | Business Wire | Biocytogen Pharmaceuticals (Peking) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), ein weltweit tätiges Biotechnologieunternehmen, das die Forschung und Entwicklung neuartiger, auf Antikörpern... ► Artikel lesen | |
| 14:36 | Ultragenyx Pharmaceutical Inc.: Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy | GlobeNewswire (Europe) | NOVATO, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New... ► Artikel lesen |